Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Delcath Systems ( (DCTH) ) has issued an update.
On March 3, 2026, Delcath Systems announced that full results from the investigator-initiated CHOPIN Phase 2 trial in metastatic uveal melanoma were published in The Lancet Oncology. The single-centre randomized study at Leiden University Medical Center evaluated percutaneous hepatic perfusion (PHP) with melphalan using Delcath’s CHEMOSAT system alone versus in combination with the immunotherapies ipilimumab and nivolumab.
The combination arm showed markedly improved outcomes, with 1-year progression-free survival of 54.7% versus 15.8%, median progression-free survival of 12.8 versus 8.3 months, and median overall survival of 23.1 versus 19.6 months, alongside higher response rates but more grade 3 or higher adverse events. Investigators and Delcath management highlighted that the superior progression-free and overall survival, enhanced hepatic control, and deeper, durable responses validate the synergy between Delcath’s liver-directed PHP and immune checkpoint inhibition, reinforcing the clinical value of the company’s platform in metastatic uveal melanoma and supporting its positioning in liver-directed oncology despite the increased toxicity profile.
The most recent analyst rating on (DCTH) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.
Spark’s Take on DCTH Stock
According to Spark, TipRanks’ AI Analyst, DCTH is a Neutral.
The score is held back primarily by weak valuation (very high P/E) and a bearish technical setup (trading below key moving averages). These are partially offset by improving fundamentals (stronger balance sheet and cash flow) and positive earnings-call guidance and catalysts, though durability and execution risks remain given historical volatility and the flagged 2025 revenue inconsistency.
To see Spark’s full report on DCTH stock, click here.
More about Delcath Systems
Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers. Its proprietary HEPZATO KIT, a combination of melphalan and a hepatic delivery system, is FDA-approved in the U.S. for liver-directed treatment of adult patients with metastatic uveal melanoma, while its CHEMOSAT device-only system is approved in Europe for percutaneous hepatic perfusion in various liver cancers.
The company’s technologies are designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and hepatotoxicity. HEPZATO KIT isolates and filters hepatic venous blood during melphalan infusion and washout, aiming to achieve meaningful tumor responses with manageable side effects, and CHEMOSAT is used at major European centers for liver-directed oncology procedures.
Average Trading Volume: 512,371
Technical Sentiment Signal: Sell
Current Market Cap: $310.3M
Find detailed analytics on DCTH stock on TipRanks’ Stock Analysis page.